Startups
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 30, 2024 | AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering | OCALA, Fla., Sept. 30, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,65... |
| Aug 16, 2024 | AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update | – Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August 16th at 8:30 AM ET OCALA, Fla., Aug. 16, 2... |
| May 31, 2024 | AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering | OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,... |
| Mar 7, 2024 | AIM ImmunoTech Announces Launch of CEO Corner Platform | |
| Jun 28, 2023 | AIM ImmunoTech 宣布在《美国癌症研究杂志》上发表一项评估 Ampligen® 治疗胰腺癌的临床前研究取得的积极结果。 | 研究结果对正在进行的早期准入计划和即将开展的临床试验工作予以支持，并表明针对 TLR-3 肿瘤水平足够的胰腺癌患者，Ampligen 或许能够抑制其肿瘤细胞生长及增强其免疫反应。 /EIN News/ -- 佛罗里达州奥卡拉, June 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)（以下简称“AIM”或“公司”）今日宣布发表临床前数据，数据表明 Ampligen 有可能直接作用于肿瘤... |
| Nov 16, 2021 | AIM IMMUNOTECH INC. : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amende... |
| Oct 19, 2021 | AIM ImmunoTech : Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer | OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the U.S. ... |
| Aug 17, 2021 | AIM IMMUNOTECH INC. : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amende... |
| May 17, 2021 | AIM IMMUNOTECH INC. AIM IMMUNOTECH INC. : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amende... |
Show more
Reviews 0
FAQ about AIM ImmunoTech
What has the press written about AIM ImmunoTech?
Parsers VC has collected 11 articles mentioning AIM ImmunoTech, among them “AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering” (Sep 30, 2024) and “AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update” (Aug 16, 2024).
Is AIM ImmunoTech still active?
Yes, AIM ImmunoTech is active; its latest activity on Parsers VC dates from Nov 18, 2024.